Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

In the falciparum malaria parasite cycle, the gametocyte stages are responsible for the transmission from person to mosquito, then to other persons. A better understanding of how gametocytes respond to malaria treatments would help us block transmission and ultimately eliminate malaria.

I’m Andrea Ruecker and I’m a postdoctoral researcher here at the malaria department in MORU in Bangkok.

Malaria is very unusual because it has a very complicated life cycle. Usually when you are infected with malaria you have the two different stages inside your red blood cells. You have the one stage that makes you very sick, we call that the asexual stage, this is when you have the disease symptoms and this is the one we have to treat otherwise you will be very sick and you may die. But at the same time you also develop these other stages inside the red blood cells which are sort of dormant; they don’t cause any disease symptoms but these are the stages - we call them gametocyte stages - which are responsible for the infectivity into the mosquito and they are solely responsible for the transmission from person to person - person to mosquito, then to another person.

We are trying to stop malaria spread by treating the patient that is sick with malaria, not just only treating the disease symptoms but also giving the person a drug that then kills those gametocyte stages, so those gametocytes can’t infect a mosquito. 

I’m enjoying this research because I really want to make a difference, I want to help people and I want to help eliminate malaria. I don’t think we can eliminate malaria unless we look at the whole package of the malaria parasite, which includes the transmission stages. Their lifecycle is very intriguing and the cell biology, from a cell biological point of view, looks very exciting. I’m trying to figure out in the lab, when I treat them with drugs, how we can stop them from developing further and we can look at this in a very fine setting in the lab. It’s just very exciting to look at them and trying to then feed that back into the field and then hopefully have an impact.

The challenges particularly in this kind of work is that we are growing those transmission stages - the gametocytes - in the lab. In a human body it takes approximately 8 to 10 or 12 days to develop before they can actually infect the mosquito to then spread malaria, and we have to grow them in the lab which takes approximately 2 weeks. But their viability is very delicate and sometimes we grow those stages for 2 weeks and then they’re not viable so we can’t do any experiments with it so they are very challenging to grow on a day to day basis.

Our research is really important because if we want to understand malaria transmission, we need to understand those transmission stages - the gametocytes - and we need to understand how they respond to drugs and vaccines. We also need to understand how they respond under the current setting of drug resistance and how drug resistance spreads. This is a very unique approach because not many places have the tools that we developed previously. We want to be able to constantly cross talk between the lab and the field and that is why I think our work really is fitting right in translational research and medicine.

Andrea Ruecker

Dr Andrea Ruecker's main research focuses on P. falciparum malaria transmission blocking interventions within the human host. She developed a novel translational toolkit and investigates the impact of antimalarial drugs on the gametocyte stages, both in vitro and in malaria patients.

More podcasts related to Malaria

Bob Taylor: Primaquine for vivax and falciparum malaria

Primaquine can be used both to treat vivax malaria and to prevent the transmission of falciparum malaria from human to mosquito. A shorter and age-based primaquine regimen would reduce the burden of vivax malaria. It would also allow primaquine to be used more widely to block the transmission of falciparum malaria.

Lisa White: Mathematical modelling for tropical diseases

Mathematical modelling, particularly when combined with economical modelling, allows researchers and policy makers to determine the most effective interventions to fight infectious diseases such as malaria. We can use those models to explore ‘what ifs’ scenarios, at country or province level, save more lives and limit costs.

Ric Price: Curing Plasmodium vivax malaria

Vivax malaria used to be considered benign but is now recognised as an important cause of morbidity and mortality. Resistance to chloroquine (given to treat the parasite blood stage) is growing and ACT (artemisinin-based combination therapy) is becoming common treatment for vivax malaria. New drugs and better public health strategies can help elimination targets, anticipated for 2030.

Olivo Miotto: Genomics and global health

Genomics is the study of the complete DNA sequence, for example of a particular parasite, allowing us to analyse its evolution and the impact of human interventions. Alongside clinical date, we use genomics to identify mutations that are markers for drug resistance. Mapping out drug resistance then helps inform elimination programmes.

Frank Smithuis: Fighting malaria in Myanmar

Although malaria is decreasing in Myanmar, resistance to anti-malarials is on the rise in the region and the focus is now to treat people early, particularly in remote communities. MOCRU has set up a network of community health workers, trained and supplied with diagnostics, bednets and treatments, to help improve access to healthcare as well as produce the evidence to encourage policy changes.

Rob van der Pluijm: Tracking antimalarial resistance and treatment of malaria using Triple ACTs

Anti-malaria drug resistance is spreading throughout Southeast Asia and we need to find new treatments. Our researchers at MORU use a combination of artemisinin and two partner drugs instead of one. If confirmed safe and tolerable, triple artemisinin combination therapies might be a good option to treat multi-drug resistant malaria, as well as slow down the emergence and spread of anti-malarial resistance.

James Watson: Primaquine and vivax malaria

Primaquine is a drug used to eliminate vivax malaria from the liver and prevent relapses. However, it causes anaemia in patients with G6PD deficiency. A new, slightly longer regimen with increasing doses of primaquine could allow to safely treat all patients with vivax malaria.

Xin Hui Chan: Using big data to eliminate malaria

Malaria is the most important parasitic infection to still affect humans, and a safe use of antimalarial drugs is paramount. The current explosion of clinical data is causing a jungle of data; making sense of all this data will greatly help us in our fight to eliminate malaria.

Bob Snow: Malaria control in Africa

Quality data is vital to design better malaria control programmes. This project helps various African countries gather epidemiological evidence to better control malaria. Professor Bob Snow showed how sub-regional, evidence-based platforms can effectively change malaria treatment policies.

Lorenz von Seidlein: Malaria elimination in the Greater Mekong sub-region

Multidrug resistant P. falciparum malaria is now established in parts of Thailand, Laos and Cambodia, causing high treatment failure rates for artemisinin combination therapies, the main falciparum malaria medicines.

Translational Medicine

From Bench to Bedside

Ultimately, medical research must translate into improved treatments for patients. At the Nuffield Department of Medicine, our researchers collaborate to develop better health care, improved quality of life, and enhanced preventative measures for all patients. Our findings in the laboratory are translated into changes in clinical practice, from bench to bedside.